BioAegis is developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin.
BioAegis Therapeutics has raised $22.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2022.
BioAegis Therapeutics is headquartered in Morristown, United States.
BioAegis is developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin.
BioAegis Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioAegis Therapeutics — Funding & Investors." VCBacked, March 22, 2022, https://www.vcbacked.co/company/bioaegis-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). BioAegis Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/bioaegis-therapeutics
{{cite web |title=BioAegis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bioaegis-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated